Related Experiment Video

Updated: Mar 29, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Current challenges in HER2-positive breast cancer

Fabio Puglisi1, Caterina Fontanella1, Vito Amoroso2

  • 1Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Udine, Italy.

Critical Reviews in Oncology/Hematology
|December 8, 2015
PubMed

Insights

Trastuzumab has improved outcomes for HER2-positive breast cancer patients. New therapies and evolving treatment guidelines offer further advancements for early and advanced disease management.

Area of Science:

  • Oncology
  • Medical treatment

Background:

  • Trastuzumab has significantly improved outcomes for patients with HER2-positive breast cancer.
  • Optimal use of trastuzumab, including in small tumors and cardiac safety, is still being defined.
  • New HER2-directed therapies are evolving the treatment landscape.

Purpose of the Study:

  • To summarize the latest evidence on HER2-positive breast cancer management.
  • To provide insights into the optimal use of trastuzumab and newer HER2-targeted agents.
  • To delineate future research and treatment perspectives.

Main Methods:

  • Review of recent clinical evidence and guidelines.
  • Synthesis of data on trastuzumab, pertuzumab, and trastuzumab-emtansine (T-DM1).
  • Analysis of treatment strategies for early and advanced HER2-positive breast cancer.

Main Results:

  • Recent evidence addresses optimal trastuzumab use in specific patient populations.
  • New therapies like pertuzumab and T-DM1 offer improved efficacy.
  • The treatment algorithm for HER2-positive breast cancer is continuously evolving.

Conclusions:

  • Current evidence supports refined use of trastuzumab and integration of novel HER2-targeted therapies.
  • Ongoing research is crucial for further optimizing treatment for HER2-positive breast cancer.
  • Future perspectives involve personalized treatment approaches and novel therapeutic strategies.
Keywords:
Breast cancerDual targetingHER2LapatinibNeoadjuvantPertuzumabTrastuzumabTrastuzumab-emtansine

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K